Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.

The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Detailed price information for Mustang Bio Inc (MBIO-Q) from The Globe and Mail including charting and trades.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

After falling 4.74% in the first quarter (Q1), the BioWorld Cancer Index (BCI) staged a strong recovery in Q2, ending the period up 12.78%. The broader markets followed a similar trajectory, with the ...

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low ...

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low ...